Kadimastem - Stem Cell to Cure Diseases
  • New Hope for ALS Patients Worldwide: Kadimastem Commences Its Clinical Trial in ALS Patients at Hadassah Medical Center

  • Robust Stem Cell
    Expansion Technologies

  • Diverse Stem Cell
    Differentiation Capabilities

  • Promising Therapeutic Programs

Cells to Cure Diseases

Kadimastem (TASE: KDST) is a clinical stage biopharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells (hESCs) to treat neuro-degenerative diseases such as ALS and Diabetes.

Kadimastem’s visionary positioning and founding principles stem from the success of Professor Michel Revel’s previous invention of a blockbuster drug.

The company is developing revolutionary regenerative therapies based on stem cells, moving away from the traditional curative therapies. The technology has been developed as a platform enabling the manufacturing of islet-like endocrine cells and glia restricted progenitors thus having potential applications for diabetes, and for neurodegenerative diseases such as ALS

News & Events